Serum-Free MSC Culture Using Vitronectin Cell Aggregates
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for producing mesenchymal stem cells from bone marrow mononuclear cells are inefficient and often contaminated with xenogeneic components, necessitating the development of a serum-free and xeno-free culture method to enhance production efficiency and purity.
Innovation Solution
Culturing bone marrow mononuclear cells containing mesenchymal stem cells in a serum-free medium on a culture container coated with vitronectin, followed by dissociation and further culture in the presence of vitronectin or its partial peptides, optionally with a TGFβ receptor inhibitor, to form and collect cell aggregates, thereby enhancing mesenchymal stem cell production.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If bone marrow mononuclear cells are cultured in a medium containing bovine fetal serum to utilize the adhesiveness of mesenchymal stem cells, then mesenchymal stem cells can be produced, but the mesenchymal stem cells become contaminated with xenogeneic components
Solution Approach 1:
The invention extracts and removes the harmful xenogeneic component (bovine fetal serum) from the culture medium while retaining the essential function of promoting mesenchymal stem cell adhesion and proliferation. This is achieved by replacing FBS with a serum-free medium that eliminates contamination risks while maintaining culture effectiveness.
Solution Approach 2:
The invention introduces an intermediary substance (vitronectin or its partial peptides) to mediate the adhesion process between mesenchymal stem cells and the culture container. This intermediary replaces the need for xenogeneic serum components while providing the necessary adhesion function through specific binding sites that promote cell attachment and proliferation.
2Productivity
If conventional culture methods are used to produce mesenchymal stem cells from bone marrow mononuclear cells, then cell production occurs, but the production efficiency is low
Solution Approach 1:
The invention changes the chemical parameters of the culture medium by introducing vitronectin or its partial peptides at specific concentrations (e.g., 1-10 μg/mL) in a serum-free environment. This parameter change optimizes cell adhesion and proliferation rates, significantly improving production efficiency and reducing culture time compared to conventional FBS-based methods.
Solution Approach 2:
The invention applies preliminary action by pre-coating the culture container with vitronectin or its partial peptides before introducing the bone marrow mononuclear cells. This preliminary preparation creates an optimal adhesion surface that enhances cell attachment efficiency from the start of culture, leading to faster and more efficient mesenchymal stem cell production.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method significantly increases the number of mesenchymal stem cells produced, making them suitable for direct use in regenerative medicine while avoiding xenogeneic contamination.
Implementation Method 1
a step of culturing the biological cell sample comprising mesenchymal stem cells in a serum-free medium in the presence of vitronectin or a partial peptide thereof capable of adhering mesenchymal stem cells
Data Source
AI summary
Mesenchymal stem cells may be efficiently obtained from a biological cell sample containing mesenchymal stem cells by:(1) culturing the biological cell sample containing mesenchymal stem cells in a serum-free medium in the presence of vitronectin or a partial peptide thereof capable of adhering mesenchymal stem cells, and(2) collecting a cell aggregate of the mesenchymal stem cells.